Drugging the undruggable RAS: Mission Possible?

被引:0
|
作者
Adrienne D. Cox
Stephen W. Fesik
Alec C. Kimmelman
Ji Luo
Channing J. Der
机构
[1] Lineberger Comprehensive Cancer Center,
[2] University of North Carolina at Chapel Hill,undefined
[3] Vanderbilt University School of Medicine,undefined
[4] Dana-Farber Cancer Institute,undefined
[5] National Cancer Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Attempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.
引用
收藏
页码:828 / 851
页数:23
相关论文
共 50 条
  • [21] Adventures in drugging undruggable targets
    Spring, David R.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2020, 63 (07): : 362 - 362
  • [22] Drugging the 'undruggable' cancer targets
    Chi V. Dang
    E. Premkumar Reddy
    Kevan M. Shokat
    Laura Soucek
    Nature Reviews Cancer, 2017, 17 : 502 - 508
  • [23] Drugging the undruggable molecules by a DNA nanorobot
    Hua Zuo
    Chengde Mao
    Science China Chemistry, 2018, 61 : 763 - 764
  • [24] Adventures in Drugging Undruggable Targets
    Spring, David
    JOURNAL OF PEPTIDE SCIENCE, 2018, 24 : S44 - S44
  • [25] Strategies for Drugging Undruggable Targets in Oncology: From K-Ras to Drug Resistance
    Shokat, Kevn M.
    CANCER SCIENCE, 2021, 112 : 959 - 959
  • [26] Drugging the undruggable molecules by a DNA nanorobot
    Zuo, Hua
    Mao, Chengde
    SCIENCE CHINA-CHEMISTRY, 2018, 61 (07) : 763 - 764
  • [27] Drugging Undruggable Molecular Cancer Targets
    Lazo, John S.
    Sharlow, Elizabeth R.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56, 2016, 56 : 23 - 40
  • [28] Drugging the undruggable using stapled peptides
    Verdine, Gregory L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [29] Drugging the undruggable steroid receptor coactivators
    Wang, Jin
    FASEB JOURNAL, 2017, 31
  • [30] Drugging the undruggable molecules by a DNA nanorobot
    Hua Zuo
    Chengde Mao
    Science China(Chemistry), 2018, (07) : 763 - 764